Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs
International Journal of Molecular Sciences · 03.09.2023 · 24 (17) · 13618
DOI: 10.3390/ijms241713618 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.09.2023. Verfasst von Ha Yeong Choi und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Dongduk Women's University, Seoul 02748, Republic of Korea. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Lung Neoplasms, Colonic Neoplasms. Die Arbeit wurde bisher 134-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
The development of targeted therapies has revolutionized cancer treatment, offering improved efficacy with reduced side effects compared with traditional chemotherapy. This review highlights the current landscape of targeted therapy in lung cancer, colorectal cancer, and prostate cancer, focusing on key molecular targets. Moreover, it aligns with US Food and Drug Administration (FDA)-approved drugs and drug candidates. In lung cancer, mutations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements have emerged as significant targets. FDA-approved drugs like osimertinib and crizotinib specifically inhibit these aberrant pathways, providing remarkable benefits in patients with EGFR-mutated or ALK-positive lung cancer. Colorectal cancer treatment has been shaped by targeting the vascular endothelial growth factor (VEGF) and EGFR. Bevacizumab and cetuximab are prominent FDA-approved agents that hinder VEGF and EGFR signaling, significantly enhancing outcomes in metastatic colorectal cancer patients. In prostate cancer, androgen receptor (AR) targeting is pivotal. Drugs like enzalutamide, apalutamide, and darolutamide effectively inhibit AR signaling, demonstrating efficacy in castration-resistant prostate cancer. This review further highlights promising targets like mesenchymal-epithelial transition (MET), ROS1, BRAF, and poly(ADP-ribose) polymeras (PARP) in specific cancer subsets, along with ongoing clinical trials that continue to shape the future of targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Dongduk Women's University, Seoul 02748, Republic of Korea.
ORCID-Profile: Ji-Eun Chang
Förderung
- National Research Foundation of Korea
Zitieren
APA
Choi, H. Y., & Chang, J. E. (2023). Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs. International Journal of Molecular Sciences, 24(17), 13618. https://doi.org/10.3390/ijms241713618
Vancouver
Choi HY, Chang JE. Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs. International Journal of Molecular Sciences. 2023;24(17):13618. doi:10.3390/ijms241713618
BibTeX
@article{Choi2023,
author = {Choi, Ha Yeong and Chang, Ji-Eun},
title = {Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {17},
pages = {13618},
doi = {10.3390/ijms241713618}
}
EUVIMED